News
4d
SurvivorNet on MSNAn Exciting Option For Difficult-To-Treat HER2+ Gastric Cancer: What New Data Means For PatientsFor the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...
5d
Sportschosun on MSNHelicobacter infection 2 to 3 times more likely to have stomach cancer...It's the second most common...This is the second highest number after thyroid cancer.Gastric cancer refers to a malignant tumor in the stomach, mainly ...
3d
GlobalData on MSNAkeso gains NMPA approval for cadonilimab to treat cervical cancerThe therapy is also approved for treating advanced gastric cancer and relapsed or metastatic cervical cancer after ...
A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...
Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...
Cancer patients given experimental treatment that programmes the body to attack rogue cells live 40 per cent longer, major research shows.
AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. | AstraZeneca’s Imfinzi has proven it can help ...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...
AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...
China NMPA approves Akeso's PD-1/CTLA-4 bispecific antibody cadonilimab for first-line treatment of cervical cancer: Hong Kong Friday, June 6, 2025, 12:00 Hrs [IST] Akeso, Inc., a ...
HCG Manavata Cancer Centre has successfully performed its first Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) ...
Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results